Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently reported additional findings from its most comprehensive clinical study yet, HYPER-H21-4. “The findings showed that DehydraTECH-CBD resulted in a statistically significant reduction in average baseline serum catestatin concentrations of 13.50 ng/mL to just 9.65 ng/mL after five weeks of dosing, representing a 28.5% drop. In addition, mean arterial pressure significantly dropped by 4.26 ± 1.26 mm/Hg following the five weeks of DehydraTECH-CBD dosing. No statistically significant reductions in catestatin concentrations were identified in the placebo group,” a recent article reads. “Given the growing demand for alternative anti-hypertensive treatments and therapies, Lexaria recognizes an opportunity and seeks to fill it. These latest results from its ambitious HYPER-H21-4 study inch the company closer to achieving that goal, ultimately becoming a leader and tapping into a pharmaceutical market that is set to be valued at $34 billion by 2030. Lexaria’s management is optimistic that DehydraTECH-CBD and its effectiveness in modulating catestatin levels could become a significant value enhancer should it eventually enter the marketplace as an approved hypertension treatment.”
To view the full article, visit https://cnw.fm/vcpT1
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text “CBDWire” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.